Latest Angioplasty Stories

Major breakthrough at DMC Cardiovascular Institute will revolutionize treatment for heart patients with coronary blood-flow disorders, says CVI President Theodore L. Schreiber, M.D. DETROIT, Jan. 8, 2013 /PRNewswire-USNewswire/ -- The Detroit Medical Center (DMC) announced today that a team of heart specialists at its Cardiovascular Institute (CVI) has successfully conducted the Midwest's first-ever "robotic-assisted" coronary revascularization to relieve heart...

ABBOTT PARK, Ill., Jan. 8, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the initiation of the ABSORB III clinical trial in patients in the United States. This randomized, controlled trial is designed to enroll approximately 2,250 patients, the majority in the United States, and compare the performance of Abbott's drug eluting Absorb((TM)) Bioresorbable Vascular Scaffold (BVS) device to the company's XIENCE((TM)) family of drug eluting stents. The start of this trial in the...

TORONTO, Jan. 8, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, declines in procedure volumes in the United States interventional cardiology (IC) market will lead to a long-term contraction. As a result of the procedure volume decline, coupled with increasing cost sensitivity, this market will show a steady contraction from a value of just under $2.5 billion in 2012 to just under $2 billion by 2017....

NATANYA, Israel, January 3, 2013 /PRNewswire/ -- Angioslide, a provider of Embolic Capture Angioplasty solutions, announced today the closing of $6.3 million financing led by new investor TriVentures. In addition Biostar joined returning investors Viola Partners, Agate and XT Investments (formerly Ofer HT) to complete the round. "Proceeds from this Series C round will be used to continue US market expansion, improve our product offering and validate the technology in...

[234 Pages Report] Neurovascular/Interventional Neurology Market research report encompasses devices for neurothrombectomy (suction/aspiration devices, clot retriever and snare), cerebral balloon angioplasty & stenting systems (carotid artery stents, distal filter devices, balloon occlusion devices), aneurysm coiling & arteriovenous malformation embolization, fistula embolization devices (embolic coil, liquid embolic agents and flow diversion devices), and support devices...

NEW YORK, Jan. 2, 2013 /PRNewswire/ -- The FREEDOM trial, the first long-term, comparative study of its kind exclusively for patients with diabetes and advanced multivessel coronary artery disease (CAD) revealed that diabetics with CAD live longer, and are less likely to suffer a non-fatal heart attack, when treated with bypass surgery instead of drug-eluting stents (DES), tiny, medicine-coated mesh tubes that prop open clogged arteries. The findings were presented in the 2012...

Some stroke patients may benefit from cerebral angioplasty and stent placement, according to a new study published online Tuesday, December 11, in the journal Radiology. Oak Brook, Ill (PRWEB) December 11, 2012 Some stroke patients may benefit from cerebral angioplasty and stent placement, according to a new study published online in the journal Radiology. “As many as 70 percent of ischemic stroke patients could have positive clinical outcomes with the additional use of intra-arterial...

Some stroke patients may benefit from cerebral angioplasty and stent placement, according to a new study published online in the journal Radiology. "As many as 70 percent of ischemic stroke patients could have positive clinical outcomes with the additional use of intra-arterial revascularization using stents," said Martin Roubec, M.D., Ph.D., a neurologist in the Comprehensive Stroke Center at the University Hospital Ostrava in the Czech Republic. Ischemic stroke, the most common form...

AUSTIN, Texas, Nov. 20, 2012 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study in patients receiving MABp1 to reduce restenosis after percutaneous revascularization of the Superficial Femoral Artery (SFA). Patients receiving MABp1 demonstrated a 58 percent reduction in Major Adverse Cardiovascular Events (MACE) and 60 percent longer patency in treated vessels compared to control patients. This...

SAN DIEGO, Nov. 19, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced a winning patent decision in Europe and successful resolution of a long-standing competition between Cardium and its licensor the University of California, and Boston Scientific Corporation (NYSE: BSX) and its licensor Arch Development, over rights to key methods for the application of cardiovascular gene therapy to the treatment of coronary heart disease, as is employed in Cardium's...